Cu entuziasm și profesionalism, Dr. Dan CĂLUGĂRU a format o echipă bine pregătită, care având la dispoziție tehnică medicală performantă, ajută la rezolvarea problemelor oftalmologice, punând întotdeauna accent pe confortul și siguranța pacienților, oferind servicii oftamologice complete la standarde înalte de calitate, atât prin experiența profesională cât și ca nivel al dotării cu aparatură. Echipa beneficiază de suportul și experiența Prof. Univ. Dr. Mihai Călugăru.
Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion
September 2019, Volume 205, Pages 200–201
Re: Bailey et al: Intralesional macular atrophy in anti-vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial (Ophthalmology. 2019;126:75–86)
September 2019, Volume 126, Issue 9, Pages e71–e72
Multiple Effects Of Intravitreal Aflibercept On Microvascular Regression In Eyes With Diabetic Macular Edema
August, 2019, Volume 09, Issue 08, pp.29071-29072
Comment on "The thickness and volume of the choroid, outer retinal layers and retinal pigment epithelium layer changes in patients with diabetic retinopathy"
August 2019, Volume 12,Issue 08, p.1366-1368
Patient Characteristics of untreated chronic central serous chorioretinopathy patients with focal versus diffuse leakage
July 2019, Volume 09, Issue 07, pp.28800-28801
Loss of peak vision in retinal vein occlusion patients treated for macular edema
July 2019, Volume 09, Issue 07, pp.28783-28784
Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser
June 2019, Volume 11, Issue 06, pp.4439-4440
A two-year study of diffused retinal pigment epitheliopathy treated with half-dose photodynamic therapy guided by simultaneous angiography and optical coherence tomography
June 2019, Volume 11, Issue 06, pp.4480-4481
Randomized Trial Of Wide-Field Guided Prp For Diabetic Macular Oedema Treated With Ranibizumab
June 2019, Volume 11, Issue 06, pp.4876-4877
Ischemic retinal vein occlusion: Characterizing the more severe spectrum of retinal vein occlusion
May–June 2019, Volume 64, Issue 3, Pages 440–441
Predictive Factors of Response to Mineralocorticoid Receptor Antagonist in Nonresolving Central Serous Chorioretinopathy
May 2019, Volume 201, Pages 87–88
Management of the open angle glaucoma in patients with central/hemicentral retinal vein occlusions
March 2019, Volume 12, Issue 3, pp.436-441
Central serous chorioretinopathy in elderly subjects: angiographic and tomographic characteristics
February 2019, Volume 11, Issue 02, pp.1614-1615
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 Phoenix Study
February 2019, Volume 198, Pages 262–263
Re: van Dijk et al: Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE trial
January 2019, Volume 126, Issue 1, Pages e10–e11
Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema
January 2019, Volume 257, Issue 1, pp. 241–242
Re: Berry et al: Association of Disorganization of Retinal Inner Layers with Ischemic Index and Visual Acuity in Central Retinal Vein Occlusion
January 2019, Volume 3, Issue 1, page e1
Comment on “Intravitreal dexamethasone implants for diabetic macular edema”
December 2018, Volume 11, Issue 12, p. 2029-2032
Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting
December 2018, Volume 196, p. 208–209
Comment on “Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration”
November 2018, Volume 11, Issue 11, p. 1884-1886
Clinical Features of Central Serous Chorioretinopathy With Type 1 Choroidal Neovascularization
November 2018, Volume 195, p. 245–246
Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the united states
October 2018, Volume 10, Issue 10, pp.74665-74666
Bun venit!
În clinica noastră se tratează peste 3000 de pacienți anual, număr în permanentă creștere, având în vedere progresul științific și tehnic de care echipa Dr. Călugăru este mereu preocupată.
Echipamentele noaste sunt furnizate de către producători consacrați în domeniu: Alcon (S.U.A), Bausch & Lomb (SUA), Blanco (Germania), Brumaba (Germania), Carl Zeiss Meditec (Germania), Spacelabs (S.U.A), Getinge (Suedia), Tomey (Japonia), Melag (Germania), Nidek (Japonia), Briot (Belgia).
Pentru operațiile de reducere a dioptriilor cu laser excimer (Lasek, Prk) nu este nevoie de analize. Pentru toate celelalte intervenții chirurgicale analizele sunt obligatorii.
Analizele necesare pentru operație:
- Hemoleucograma
- Coagulograma
- Glicemie
- Uree
- VSH
- AST
- ALT
- Bilirubina totală
- HVB
- HVC
- HIV
- Consult cardiologic
- EKG
Pentru a reuși vindecarea unui număr cât mai mare de pacienți echipa Dr. Călugăru colaborează cu mai mulți medici specializați în oftalmologie, opticieni și optometriști, cât și cu medicii de familie din zonele învecinate.